SLNO Matthew Pauls sells $425K worth of shares
Apr 01, 2025, 4:33 AM
0.00%
What does SLNO do
Soleno Therapeutics, a clinical-stage biopharmaceutical company based in Redwood City, California, focuses on developing novel therapeutics for rare diseases, notably DCCR for Prader-Willi syndrome. DCCR, a once-daily oral tablet, recently completed Phase 3 trials and has received Fast-Track and orphan designations in the U.S. and EU.
Matthew Pauls sold 5,937 shares of SLNO on 28 March at $71.55 per share, worth a total of $425K. They now own 6,500 SLNO shares, or a 48% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.